Anti-TNF-α may be an attractive therapeutic option in AOSD with a predominant articular pattern (Gerfaud-Valentin et al., 2014), while IL-1β inhibitors are more effective for the systemic manifestations (Vitale et al., 2016). This evidence concerns the gene TNF and adult-onset Still disease.